Dr. Zhenyu He 何振宇
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical radiation oncology, with a focus on breast cancer (radiation and comprehensive care), nasopharyngeal carcinoma, lung cancer, and esophageal cancer.
Dr. He studied at Sun Yat-sen University of Medical Sciences from 1996 to 2001. Since 2001, Dr. He has worked at Sun Yat-sen University Cancer Center as a Chief Physician specializing in clinical radiation oncology.
Name order: in Chinese the family name comes first (He Zhenyu). Papers usually list the name as Zhenyu He or He Z.
Selected publications
161 papers on PubMed matched by name and affiliation; 58 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cancer Res, 2026 (senior author): The PDGFB-DDX5 axis contributes to breast cancer radioresistance through HR-associated DNA repair. PubMed 42911100
- Cancer Med, 2026 (senior author): The Clinical Relevance of Lymph Node Ratio for Post-Mastectomy Radiotherapy in Triple-Negative Breast Cancer: A Real-World Analysis With Propensity Score Matching Using SEER Database. PubMed 42043849
- Breast, 2025 (senior author): Postoperative radiation therapy in localized breast malignant phyllodes tumors: RPA-derived risk model identifies high-benefit subgroups with local control improvement. PubMed 41135329
- Ann Hematol, 2025 (senior author): Initial local treatment strategies on survival outcomes of early-stage breast mucosa-associated lymphoid tissue lymphoma. PubMed 40839034
- BMC Cancer, 2025 (senior author): Integrative analysis identifies radiotherapy resistance-associated CAF subtypes shaping the tumor immune landscape in breast cancer. PubMed 41107799
- Gland Surg, 2025 (senior author): Postmastectomy radiotherapy indications using pathological prognostic staging in node-positive breast cancer. PubMed 40671775
- Clin Breast Cancer, 2024 (senior author): Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races. PubMed 38007348
- Cell Signal, 2023 (first author): CircNCOR1 regulates breast cancer radiotherapy efficacy by regulating CDK2 via hsa-miR-638 binding. PubMed 37391048
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion